Bio-Techne Corporation (TECH) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
614 McKinley Place N.E.
Minneapolis, MN 55413
United States of America (the)
Phone
612 379 8854
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3100
First IPO Date
February 09, 1989
| Name | Title | Pay | Year Born |
| Kim Kelderman | Chief Executive Officer, President & Director | 2.29M | 1968 |
| Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | 835,661 | 1975 |
| William A. Geist | President of Protein Sciences Segment | 1.34M | 1969 |
| James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | 1.67M | 1971 |
| Gerry Andros | Vice President of Sales and Marketing | 0 | N/A |
| Luca Cicchetti | Managing Director | 0 | N/A |
| Martin Wirtz | Senior Vice President of Strategy & Corporate Development | 0 | N/A |
| Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
| Gary J. Latham | Vice President & Chief Technology Officer | 0 | N/A |
| David Clair | Vice President of Investor Relations & Corporate Development | 0 | N/A |
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.